Piramal approves $20m capacity expansion for hormonal, ADC manufacturing
![Piramal approves $20m expansion for hormonal, ADC manufacturing](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_large/publications/pharmaceutical-science/biopharma-reporter.com/article/2015/01/16/piramal-approves-20m-expansion-for-hormonal-adc-manufacturing/1048551-2-eng-GB/Piramal-approves-20m-expansion-for-hormonal-ADC-manufacturing.png)
Contract manufacturer Piramal recently approved a $20m capacity expansion for hormonal and antibody drug conjugate (ADC) manufacturing at its facilities in Morpeth, UK, and Grangemouth, Scotland.
The expansions come as the company also recently invested $40m in new equipment and technologies and related infrastructure. The company said the investments were part of a broader plan to better serve its customers.
On the ADC side, Piramal has invested steadily from a 2011 capacity expansion to a $2.5m expansion in 2013.
In addition, the company recently completed a $10m green field facility to double its discovery services capacity.